Targeting the Stroma in the Management of Pancreatic Cancer

Penelope Edwards†, Byung Woog Kang‡ and Ian Chau*†

*Department of Medicine, Royal Marsden Hospital, London, United Kingdom, ‡Department of Oncology/Hematology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea

Pancreatic cancer (PC) presents extremely aggressive tumours and is associated with poor survival. This is attributed to the unique features of the tumour microenvironment (TME), which is known to create a dense stromal formation and poorly immunogenic condition. In particular, the TME of PC, including the stromal cells and extracellular matrix, plays an essential role in the progression and chemoresistance of PC. Consequently, several promising agents that target key components of the stroma have already been developed and are currently in multiple stages of clinical trials. Therefore, the authors review the latest available evidence on novel stroma-targeting approaches, highlighting the potential impact of the stroma as a key component of the TME in PC.

Keywords: pancreatic cancer, stroma, immune checkpoint inhibition (ICI), hyaluronic acid, hedgehog (Hh), bruton kinase inhibitor, SPARC

INTRODUCTION

Pancreatic cancer (PC) has a 5-year survival rate of less than 8% (1). The treatment of operable PC involves surgery and adjuvant chemotherapy, yet only around 20% of patients present with an operable disease (2). Even for patients who achieve R0 surgical resection, the likelihood of local relapse is 20% and metastatic disease is 80%. For inoperable patients, chemotherapy is offered, yet the response rate (RR) is generally low with only a marginal improvement in efficacy. In a metastatic setting, triplet therapy includes folic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), which has a median overall survival (OS) of 11.1 months (3). Comparatively, the OS for gemcitabine alone is 6.6 months, with a modest improvement to a 8.7 months when adding nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (4, 5). Despite the recent development of new chemotherapeutic regimens, patients with PC still show a dismal prognosis, thus new treatment options are urgently required.

The dense stromal formation surrounding PC and tumour microenvironment (TME) contributes to the aggressiveness of PC (6). The stromal cells consist of cancer-associated fi broblasts (CAFs), immune cells, and endothelial cells, while the extracellular matrix (ECM) includes collagen, fi bronectin, glycosaminoglycan, hyaluronic acid (HA), and proteinases (7). In particular, the fi brotic reaction and desmoplastic TME are generally related with the recruitment and activation of CAFs, extensive infiltration of ECM components, and an altered tumour vasculature (8). Current evidence suggests that this stromal remodelling is directly involved in tumourigenesis and cancer progression (9). Moreover, the fi brotic reaction inhibits the immune response, which is impaired as a result of several immunosuppressive mechanisms (10). Therefore, new treatment strategies that target the tumour stroma may be effective for patients with PC.
Cancer research studied the factors that promote normal pancreatic cells to develop into preneoplastic lesions and eventually to invasive cancer (11). Activating mutations have been found in Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS), p16, and p53, plus around 10% of PC has been found to have a hereditary or genetic component, with germline alterations most commonly related to breast cancer gene 2 (BRCA2) and others (12, 13). Recently, following a comprehensive integrated genomic analysis of 456 pancreatic ductal adenocarcinomas using various platforms, the Cancer Genome Atlas Research Network (TCGA) proposed four distinct subtypes: squamous, aberrantly differentiated endocrine exocrine (ADEX), pancreatic progenitor, and immunogenic tumours (14). Interestingly, the squamous and immunogenic subtypes are especially related to the TME than the tumour cells (11). Another recent investigation also established a stromal classification with two subtypes ECM-rich and immune-rich, where the ECM-rich subtype was associated with a shorter survival compared to immune-rich tumours (15). Similar to this classification, digital deconvolution of transcriptomic data identified two distinct stromal-specific gene expression signatures: normal and activated, where normal stroma was dominated by markers for pancreatic stellate cells (PSCs), whereas activated stroma was characterized by inflammatory signatures associated with a significantly worse prognosis (16). Consequently, based on a better molecular characterization of PC that includes the stroma, targeting the appropriate stromal components may lead to a better outcome and represent a promising approach for precision medicine in PC treatment.

**ROLE OF DESMOPLASTIC STROMA IN TUMOUR MICROENVIRONMENT OF PANCREATIC CANCER**

A desmoplastic stroma helps to define PC and is the basis of a complex TME (17). As mentioned above, a desmoplastic stroma is a very complex and heterogeneous network, and organized by interactions among various cell types and acellular components (9) (Figure 1).

CAF s are a major cellular component of PC stroma and derived from several origins, such as PSCs, fibroblasts, and epithelial, endothelial, and mesenchymal cells, through multiple activation pathways including epithelial-mesenchymal transition (EMT) (18, 19) (Table 1). PSCs are major sources of CAFs and found in the peri-accinar, perivascular, or periductal sites of the exocrine pancreas (26–28). In the case of activation, PSCs transform into a myofibroblast-like phenotype that can support pancreatic fibrosis and tumour growth in PC (20). Moreover, adipocytes, pericytes, monocytes, endothelial cells, and bone marrow-derived or adipose-derived mesenchymal stem cells can differentiate into CAFs (21–25). These diverse origins of CAFs may explain their multiple roles and abilities in terms of tumour growth and progression in PC (29). These pathways are inactive in normal tissue, yet activated by secreted factors, such as tumour necrosis factor α (TNFα), transforming growth factor β (TGF-β), platelet derived growth factor (PDGF), interleukins, and sonic hedgehog (SHh), where these activated,
specialized forms of fibroblasts express alpha-smooth muscle actin (αSMA), stromal cell-derived factor 1 alpha, fibroblast activation protein, and fibroblast specific protein-1 (7, 30). Once activated, CAFs are known to work as a key component of the TME with diverse functions, including matrix remodelling, metabolic effects, and immune crosstalk (29). CAFs are also a substantial source of growth factors, cytokines and exosomes that can induce the characteristic desmoplasia of the stroma. CAFs eventually promote various tumour-promoting processes, including cancer cell growth, proliferation, metastasis, and tumour angiogenesis and contribute to tumour therapy resistance (31) (Figure 2). Ohlund et al. recently identified two distinct populations of inflammatory fibroblasts (iCAFs) and myofibroblasts (myoCAFs) in PC (32). myoCAFs are located in close proximity to tumour cells and express high levels of αSMA, while iCAFs are localized at distal sites and exhibit low levels of αSMA and high levels of inflammatory mediators, contributing to an immunosuppressive environment (18, 29).

The ECM contains proteins, such as collagen, integrin, several types of glycans, and multiple soluble factors, with diverse physical and biochemical properties (33). These factors function as a dynamic molecular system that controls cells by altering proliferation, cytoskeletal organization, cellular differentiation, and receptor signalling (34). The predominant glycosaminoglycan is HA, which increases tumour tissue stiffness, promotes metastasis, and regulates tumour immunity (35). Under normal circumstances, the amount of HA is controlled by a balance between synthesis and degradation (36). However, this balance can be shifted towards a higher concentration in PC and this HA-rich microenvironment can then promote tumour proliferation by enhancing cell growth, migration, invasion, EMT, and metastasis (36, 37).

![FIGURE 2](image_url) | Activation and diverse functions of cancer-associated fibroblasts (CAFs).
Several studies have reported increased expression of HA and its receptors in PC tissues, which is also associated with poor prognosis (38). In vitro studies have also revealed that HA can stimulate PC cell migration. Moreover, animal studies found accelerated tumour growth from the accumulation of extracellular HA due to the forced expression of synthesizing genes (39). In addition to its significant tumour-promoting effects, HA increases the interstitial fluid pressure, thereby compressing intratumoural blood vessels and resulting in hypoxia. This hypoxia may induce angiogenesis and, in an experimental model, the induction of HA overproduction was found to accelerate angiogenesis through stromal cell recruitment (40).

Along with HA, extracellular proteins, including connective tissue growth factor (CTGF) and secreted protein acidic and rich in cysteine (SPARC) are also essential for maintaining physiologic homeostasis and modulate multiple biologic processes, such as wound repair, tissue remodeling, angiogenesis, matrix cell adhesion, cell differentiation, proliferation, and migration (9, 41). The functions of these molecules might be in part mediated by interaction with PSCs/CAFs and several growth factors, like TGF-β and fibroblast growth factor (FGF) (16). Although the role of ECM components in carcinogenesis remains controversial in PC, they are highly expressed in various types of cancer (42). Plus, several studies have demonstrated that overexpression of ECM components generally indicates a worse prognosis in PC (43). Thus, when taken together, ECM components could represent a promising therapeutic target in the treatment of PC.

PC is also characterized by excessive dense ECM deposition associated with vasculature collapse and limited oxygen delivery, promoting the induction of an invasive and treatment-resistant phenotype (44, 45). In response to hypoxia, PC tumour cells produce several angiogenic molecules, including hypoxia-inducible factors (HIFs), vascular endothelial growth factors (VEGFs), FGFs, PDGF, Matrix metalloproteinase 9 (MMP-9), and interleukin-8. Hypoxia-promoted changes lead to increased tumour proliferation, metabolic changes, and also contribute to tumour inhibition (81). Such preclinical studies led to a phase Ib study by Hingorani et al. to evaluate the safety and efficacy of escalating doses of intravenous PEGPH20 combined with gemcitabine in patients with metastatic PC (62). The combination was well tolerated and demonstrated therapeutic benefit in 28 patients. Plus, patients with high levels of HA expression showed an improved objective response and median survival. These results then prompted an investigation of PEGPH20 with gemcitabine plus nab-paclitaxel in the phase II HALO 202 trial (82). However, stage one produced an imbalance from an improved median PFS (6.0 months, \( P = 0.049 \)) and the TE events were comparable after phase one (82). Moreover, stage two using PEGPH20 with gemcitabine plus nab-paclitaxel in the phase II HALO 202 trial (82). However, stage one produced an imbalance from an improved median PFS (6.0 months, \( P = 0.049 \)) and the TE events were comparable after phase one (82). Therefore, these findings suggest that strategies that can alter the immune suppressive stroma and restore T-cell-mediated immune surveillance may potentially improve the outcome for PC patients.

### THERAPEUTIC STRATEGIES TARGETING STROMAL CELLS IN PANCREATIC CANCER

Several promising agents that target key components of the stroma have already been developed and are currently in multiple stages of clinical trials in PC (Table 2).

#### Hyaluronic Acid

Targeting HA deposition can be divided into 3 approaches: depleting stromal HA, inhibiting HA synthesis, and blocking HA signalling (79). In a mouse model, pegvorhyaluronidase alfa (PEGPH20), the PEGylated form of a recombinant human hyaluronidase, has been shown to deplete or reduce HA within the stroma, thereby improving tumour perfusion and drug delivery (80). Moreover, when combined with chemotherapy, PEGPH20 exhibited a synergistic effect with substantially tumour inhibition (81). Such preclinical studies led to a phase I b study by Hingorani et al. to evaluate the safety and efficacy of escalating doses of intravenous PEGPH20 combined with gemcitabine in patients with metastatic PC (62). The combination was well tolerated and demonstrated therapeutic benefit in 28 patients. Plus, patients with high levels of HA expression showed an improved objective response and median survival. These results then prompted an investigation of PEGPH20 with gemcitabine plus nab-paclitaxel in the phase II HALO 202 trial (82). However, stage one produced an imbalance of thromboembolic (TE) events for patients receiving PEGPH20, therefore, the study protocol was revised to exclude high-TE-risk patients and include prophylactic enoxaparin. In stage two using the revised protocol, the primary endpoints were progression-free survival (PFS) and the incidence of TEs. The randomized study of 279 patients with untreated metastatic PC administered PEGPH20 plus chemotherapy or chemotherapy alone. The patients that received PEGPH20 plus gemcitabine and nab-paclitaxel benefited from an improved median PFS (6.0 versus 5.3 months, \( P = 0.049 \)) and the TE events were comparable after including enoxaparin. The benefit was even more pronounced in
| Target | Agents | Phase | Setting | Treatment arms | N  | PE  | RR (%) | PFS (months) | OS (months) | Reference |
|--------|--------|-------|---------|----------------|----|-----|--------|--------------|-------------|-----------|
| Hyaluronic acid | PEGPH20 | II | First-line | PEGPH20/Gemcitabine/Nab-paclitaxel | 116 | 40 | 6.0 | 9.6 | (62) |
| | PEGPH20 | III | First-line/HA-high | PEGPH20/Gemcitabine/Nab-paclitaxel | 113 | 33 | 5.3 | 9.2 | (63) |
| | PEGPH20 | II/II | First-line | PEGPH20/mFOLFIRINOX | 55 | 33 | 4.3 | 7.7 | (64) |
| CTGF | Pamrevlumab (FG-3019) | I/II | LAPC | Pamrevlumab/Gemcitabine/Nab-paclitaxel | 37 | - | 30 | - | (65) |
| Hh pathway | Vismodegib | II | First-line | Vismodegib/Gemcitabine/Nab-paclitaxel | 71 | - | 40 | 5.4 | 9.8 | (66) |
| FAK | Defactinib | I (exp.) | Refractory solid tumour/PC | Defactinib/Gemcitabine/Pembrolizumb | 43 | - | - | 4.7 | 10.1 | (67) |
| HGF pathway | Cabzantinib | I | First- or Second-line | Cabzantinib/Gemcitabine | 12 | - | - | 4.7 | 10.1 | (67) |
| SPARC | Nab-paclitaxel | I/II | First-line | Gemcitabine/Nab-paclitaxel | 67 | - | 48 | 7.1 | 10.3 | (68) |
| BTK | Ibrutinib | III | First-line | Ibrutinib/Gemcitabine/Nab-paclitaxel | 211 | OS/ PFS | 29 | 5.7 | 9.2 | (69) |
| Antiangiogenic agents | VEGF | Bevacizumab | III | First-line | Bevacizumab/Gemcitabine/Erlotinib | 306 | OS | 13.5 | 4.6 | 7.1 | (70) |
| | Bevacizumab | III | First-line | Bevacizumab/Gemcitabine | 301 | 8.6 | 3.6 | 6.0 | (71) |
| | VEGFR | Axitinib | III | First-line | Axitinib/Gemcitabine | 314 | OS | 12 | 4.4 | 8.5 | (72) |
| | VEGFR | Sorafenib | III | First-line | Sorafenib/Gemcitabine | 52 | PFS | 23 | 3.8 | 8.0 | (73) |
| | VEGF | Aflibercept | III | First-line | Aflibercept/Gemcitabine | 271 | OS | - | 3.7 | 6.5 | (74) |
| Immunotherapy | Vaccine | GVAX/CRS-207 | II | Second-line or more | GVAX/Cy → CRS-207 | 61 | OS | 0 | - | 6.0 | (75) |
| | | GVAX/CRS-207 | IIb | Second-line or more | GVAX/Cy → CRS-207 | 29 | 0 | - | 3.4 | (38) |
| | | | | | | | | | | | |
| ICIst | CTLA4 | Ipilimumab | II | LAPC or metastatic | Ipilimumab | 27 | - | 0 | - | 4.5 | (76) |
| Dual ICIs | CTLA4/PD-1 | Ipilimumab/Nivolumab | I/II | Solid tumours | Ipilimumab/Nivolumab | - | - | - | - | (77) |
| | CTLA4/PD-L1 | Tremelimumab/Durvalumab | II | Second-line | Tremelimumab/Durvalumab | 32 | RR | 3.1 | 1.5 | 3.1 | (77) |
| | ICIs/CTx | Pembrolizumab | I/II | First-line | Pembrolizumab/Gemcitabine/Nab-paclitaxel | 11 | CR | 27 | 9.1 | 15.0 | (78) |
| | CTLA4/PD-L1/ CTx | Tremelimumab/Durvalumab | II | First-line | Tremelimumab/Durvalumab/Gemcitabine/Nab-paclitaxel | 190 | - | - | - | (79) |
| | ICIs/Others | Pembrolizumab/GVAX/ CRS-207 | II | metastatic | Pembrolizumab/CRS-207/Epacadostat ± GVAX/Cy | 70 | - | - | - | (79) |
| | PD-1/Vaccine | Nivolumab/GVAX/CRS-207 | II | metastatic | Nivolumab/CRS-207/GVAX/Cy | 93 | - | - | - | (79) |

(Continued)
Table 2 | Continued

| Target               | Agents                          | Phase       | Setting | Treatment arms | N  | PE | RR (%) | PFS (months) | OS (months) | Reference     |
|----------------------|---------------------------------|-------------|---------|----------------|----|----|--------|--------------|-------------|---------------|
| CTLA4/PD-1/          | Ipilimumab/Nivolumab/GVAX/CRS-207 | metastatic | Ipilimumab/Nivolumab/GVAX/CRS-207 | 63 | Ongoing | NCT03190265 |
| Vaccine              | PD-L1/                            | metastatic | Atezolizumab/PEGPH20               | 40 | Ongoing | NCT03979066 |
| Hyaluronic acid      |                                    |             |         |                |    |    |        |              |             |               |

N, patient number; PE, Primary endpoint; RR, response rate; PFS, progression-free survival; OS, overall survival; PEGPH20, pegvorhyaluronidase alfa; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; TE, thromboembolic events; mFOLFIRINOX, leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin; CTGF, connective tissue growth factor; LAPC, locally advanced pancreatic cancer; Hh, hedgehog; FAK, focal adhesion kinase; esp., expansion; PC, pancreatic cancer; HGF, hepatocyte growth factor; SPARC, secreted protein acidic and rich in cysteine; BTK, bruton tyrosine kinase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; Cy, cyclophosphamide; ICIs, immune checkpoint inhibitors; CTx, chemotherapy; CR, complete response.

patients with HA-high tumours, showing a median PFS of 9.2 months for the PEGPH20 arm versus 5.2 months for the control arm (P=0.048). The proportion of patients with HA-high tumours was 34% as defined as extracellular matrix HA staining ≥50% of tumour surface at any intensity. Notwithstanding, the PEGPH20 treatment was also associated with an increased incidence and severity of other manageable adverse events (AEs), such as fatigue, muscle spasms, arthralgia, edema, and neutropenia.

Due to encouraging phase I and II studies, PEGPH20 was investigated in the phase III Halo 301 trial (NCT02715804), which used a combination of PEGPH20 and gemcitabine plus nab-paclitaxel in previously untreated patients with stage IV HA-high PC (63, 83). In this study, the HA status was prospectively determined using a VENTANA HA assay, with HA-high defined as ≥50% staining of a tumour sample. The primary endpoint was OS, with PFS, the objective RR, and safety included as secondary study endpoints. According to predefined criteria, 494 patients with HA-high PC were randomly assigned in a 2:1 ratio to receive first-line chemotherapy with gemcitabine and nab-paclitaxel in combination with either PEGPH20 or a placebo, and prophylactic enoxaparin was given for the TE risk. However, HALO 301 did not meet its primary endpoint of OS (11.2 months versus 11.5 months, P=0.97) (63, 84). Moreover, the combination arm did not improve the PFS or duration of response. This negative finding could imply that targeting the stromal component can affect resistance to chemotherapies or be attributed to compensatory mechanisms overcoming tumour stroma inhibition, suggesting that targeting desmoplasia alone is not sufficient and a combination of stromal modifying agents is needed. The results from the HALO 301 trial are also consistent with the results from a recently presented randomized phase II/II study (SWOG S1313) evaluating the efficacy of PEGPH20 and modified FOLFIRINOX in patients with metastatic PC. This trial closed early due to an inferior survival and significantly higher AEs in the combination arm (64). Consequently, new studies using PEGPE20 include the addition of immune checkpoint inhibitors (ICIs) (NCT03634332, NCT03979066). The therapeutic potential of PEGPH20 combined with an immune checkpoint inhibitor was studied in a murine syngeneic breast tumour model (85). The combination of PEGPH20 with oncolytic reovirus therapy and anti-programmed cell death protein ligand-1 (PD-L1)-targeting antibody (anti-PD-L1) resulted in enhanced anti-tumour activity and also extended survival. In addition, PEGPH20 facilitated the infiltration of cytotoxic T lymphocytes and improved the delivery of chemotherapy and programmed cell death protein-1 (PD-1)/PD-L1 antibodies (86). Therefore, these data suggest that the removal of HA by PEGPH20 can increase the efficacy of immune checkpoint therapy and also enhance the accumulation of immunotherapeutic antibodies in HA-rich tumours. Plus, PEGPE20 is also being tested as a main drug in biomarker-driven trials (NCT03193190).

Connective Tissue Growth Factor
CTGF is a profibrotic extracellular protein with an abundantly elevated expression in PC (16). CTGF is mediated by chemokine signalling, which promotes fibrosis and collagen deposition, which in turn causes cancer progression and metastasis (87, 88). Pamrevlumab (FG-3019), a fully human, recombinant DNA-derived IgG1 kappa monoclonal antibody against CTGF, attenuates the malignant properties of different human cancers and is currently under clinical trial for the treatment of PC. In a preclinical setting using a mouse model, enhanced antitumour activity was observed when using pamrevlumab as a single agent or in combined with gemcitabine (50, 89). In a phase I study, the safety and efficacy of increasing doses of pamrevlumab were evaluated in combination with two chemotherapy agents, gemcitabine and erlotinib, in 75 patients with previously untreated Stage III/IV PC (65). The results showed that pamrevlumab was well tolerated with no dose-limiting toxicity or dose-related trends in the type or incidence of serious AEs. In a subsequent phase I/II study using gemcitabine/nab-paclitaxel with pamrevlumab or gemcitabine/nab-paclitaxel alone for patients with locally advanced PC, pamrevlumab combination arm showed a higher percentage of surgical resection (33.3% versus 7.7%) and improved median survival rate, plus the combination was feasible and well tolerated with no incremental safety signals (90). Accordingly, a phase III (LAPIS) trial is currently ongoing to investigate the efficacy of pamrevlumab plus gemcitabine with nab-paclitaxel in locally advanced, unresectable PC (NCT03941093).

Hedgehog Pathway
The Hh signalling pathway is one of twelve core signalling pathways and processes in PC and plays a critical role in regulating the dense stroma of pancreatic cancer in vivo and in vitro (91, 92). Saridegib (IPI-926) is a potent and specific inhibitor of smoothened (Smo), a key signalling transmembrane protein in the Hh pathway (93). Preclinical studies using a mouse model showed that saridegib depleted tumour-associated stromal tissue and increased the
intratumoural mean vessel density, leading to a decreased tumour burden and prolonged survival (94). However, subsequent human clinical trials failed to show a sustained benefit for this agent (95, 96). Vismodegib (GDC-0449) is another Hh pathway inhibitor that blocks Hh signalling by binding to Smo (93). Similarly, in contrast to preclinical results, the addition of vismodegib to chemotherapy did not improve the overall outcomes in phase I and II studies (66, 97). Therefore, these disappointing results suggest that inhibiting the Hh pathway ironically stimulates aggressive PC clones and invigorates the metastatic capacity (59). Plus, the inhibition of CAFs via suppressing the Hh signalling pathway may induce a decreased immune response and vascular dysfunction, revealing the complex relationship between Hh signalling and desmoplastic stroma (91). Therefore, there are currently no ongoing studies on Hh signalling inhibitors in PC, except for the biomarker-driven trial (NCT02465060).

**Focal Adhesion Kinase**

Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase that plays a central role in the collagen pathway and regulates integrin-mediated ECM signalling (98). FAK is frequently overexpressed and dysregulated in a variety of cancers, including PC, and correlated with poor prognosis (98, 99). Interestingly, in preclinical studies, FAK activation induced a fibrotic and immunosuppressive TME, while inhibition of the FAK pathway was found to interrupt the aggressive effects of collagens on PC biology (100, 101). Therefore, these observations led to an investigation of a combination therapy of FAK inhibitors with gemcitabine and pembrozilumab, a humanized monoclonal antibody directed against PD-1. Defactinib (V6-6063) is a selective, orally active, competitive adenosine triphosphate (ATP) inhibitor of FAK. A recent phase I/IIa clinical trial evaluated a dose escalation of defactinib in combination with pembrozilumab and gemcitabine for patients with advanced solid tumours, and subsequently at an optimal dose for an expanded patient cohort with PC (102). Preliminary data have shown that the combination therapy was well-tolerated with no dose-limiting toxicity (DLT), and the common treatment-related AEs included fatigue, nausea, myalgia, vomiting, anorexia, pruritus, and fever. The expanded patient cohort is currently being investigating with pending correlative and efficacy data (103). Another phase II study of defactinib plus pembrozilumab is also ongoing for resectable PC patients (NCT03727880).

**Hepatocyte Growth Factor Pathway**

Hepatocyte growth factor (HGF), also known as scatter factor, is the ligand of c-Met (mesenchymal-epithelial transition tyrosine kinase receptor or HGF receptor) that is often secreted by stromal cells and regulates the stromal-tumour interactions in PC (104). The binding of HGF to c-Met leads to the dimerization and phosphorylation of c-Met and triggers several downstream signalings (105). This axis also plays an important role in the pathogenesis of pancreatic cancer and its progression. C-Met overexpression has already been identified in PC and correlated with aggressive disease (106), while elevated serum HGF levels have been associated with disease progression (107). Plus, c-Met activation has been linked with resistance to gemcitabine (108). Interestingly, *in vitro* and *in vivo* models have shown that crizotinib, an ATP competitive multi-target protein kinase inhibitor, increases sensitivity to gemcitabine and inhibits peritoneal dissemination (109, 110). A recent preclinical study demonstrated that the inhibition of both HGF and c-Met combined with gemcitabine improved the reduction of tumour volume and metastasis (105). Another report also indicated that long-term treatments involving cabozantinib induced less resistance and even improved the efficacy of gemcitabine (108). Therefore, these preclinical studies led to a phase I trial of cabozantinib, an orally bioavailable c-Met inhibitor, and gemcitabine in advanced PC (67). This trial involved the treatment of 12 patients and no maximum tolerated dose was determined, plus the DLT was relatively high at all dose levels. Another phase II clinical trial investigated the safety and antitumor activity of cabozantinib combined with atezolizumab in patients with PC (NCT04820179). Thus, several preclinical and early clinical studies have tested the inclusion of c-Met inhibitors, such as rilotumumab, crizotinib, capmatinib, and tivantinib, in combination treatments for solid tumours (104). However, the remaining major challenge is to identify potential predictive biomarkers to facilitate the appropriate selection of specific patient populations most likely to benefit from combination therapies.

**Secreted Protein Acidic and Rich in Cysteine**

SPARC is a multifunctional calcium-binding glycoprotein which modulates interactions between cells and the extracellular environment, thereby participating in cell development, matrix cell adhesion, wound repair, tissue remodeling, and angiogenesis (41, 111). SPARC may also influence PC cell proliferation, migration, metastatic, and escape mechanisms (112). Thus, SPARC has been investigated as a potential therapeutic target, where the presence of SPARC in the tumour stroma could be used to deliver albumin-conjugated molecules into the tumour and TME. Meanwhile, nab-paclitaxel, a nanoparticle form of paclitaxel, is known to deplete tumour stroma through interaction between albumin and SPARC (5). Plus, nab-paclitaxel has exhibited clinical antitumour activity in several cancer types that overexpressed SPARC (43, 113). In metastatic PC, nab-paclitaxel was used in multiple-stage clinical trials, where the addition of nab-paclitaxel to gemcitabine showed activity and efficacy in first-line treatment, improving survival and the overall RR (112, 114). Interestingly, patients with high stromal-SPARC expression exhibited a significant increase in OS compared to patients with low stromal-SPARC expression (17.8 *versus* 8.1 months), representing a significant predictor of OS in a multivariate analysis (68). Based on these results, a large, open-label, international, randomized, phase III trial (Metastatic Pancreatic Adenocarcinoma Clinical Trial, MPACT) followed with 861 metastatic PC patients as a first-line setting (5). The patients were randomly assigned 1:1 to receive either nab-paclitaxel plus gemcitabine or gemcitabine alone. As mentioned above, since the trial met its primary endpoint of OS, this combination is now a standard regimen in the treatment...
of metastatic PC. However, the stromal and tumour levels of SPARC, measured by immunohistochemistry, showed no association with survival (115, 116). These conflicting results on SPARC as a prognostic and predictive biomarker in PC may have been impacted by different methodologies of protein detection and staining evaluation, the origin of the tumour samples, and the level of the cutoff value. Moreover, recent data has suggested that specific tumour delivery of nab-paclitaxel is not directly related to SPARC expression, and nab-paclitaxel does not usually deplete tumour stroma (117). Furthermore, the efficacy of nab-paclitaxel may be dependent on the drug internalization by TAMs (118). Consequently, for PC patients, the potential link between SPARC expression and treatment efficacy remains unclear, and more precise methods are needed to analyse SPARC expression. Plus, discovering a novel targeted nanoparticle and enhanced drug delivery system using SPARC could improve the pharmacologic and therapeutic properties of conventional cancer treatment for patients with PC.

**Bruton Tyrosine Kinase**

Ibrutinib is a first-generation Bruton tyrosine kinase (BTK) inhibitor that irreversibly binds to cysteine at position 481 in the kinase domain and blocks enzyme activity (119). Protein tyrosine kinase BTK, which is essential for B cell maturation and expressed by other immune cell populations, has been implicated in the immune regulation and function of myeloid cells (120, 121). BTK has also been shown to exhibit anti-fibrotic effects in PC by effectively inhibiting the infiltration of mast cells in both transgenic mice and patient-derived xenograft models. Furthermore, ibrutinib reduces stromal fibrosis and inhibits tumour progression (122). Preclinical data for ibrutinib plus gemcitabine showed enhanced antitumour activities versus gemcitabine alone in both transgenic mouse and patient-derived xenograft PC models (122). Early developmental clinical trials also showed preliminary efficacy in solid tumours, including PC (NCT02562898) (123). Thus, based on these encouraging results, ibrutinib was included in a recent randomized phase III RESOLVE trial (NCT02436668) that assessed ibrutinib in combination with gemcitabine and nab-paclitaxel or a placebo plus chemotherapy as the first-line treatment for patients with metastatic PC (124). Although the full results have yet to be published, it has been revealed that the study failed to meet its primary endpoint of prolonged PFS and no statistically significant PFS or OS benefit was shown when adding ibrutinib to chemotherapy (69). Although both treatment arms showed a similar proportion of patients with grade ≥3 AEs, the patients in the ibrutinib arm were treated for a shorter time period and received lower cumulative doses of all agents compared with the placebo arm. Therefore, this emphasizes the need for clinical biomarkers to predict the sensitivity and resistance to BTK inhibitors and identify the best combination partners for synergistic effects and lower toxicity. Despite these disappointing results, more recent studies are investigating the combination of BTK inhibitors with ICIs. Indeed, multiple cell types, such as MDSCs, macrophages, dendritic cells, and endothelial cells, in the TME are regulated by BTK (119). In a preclinical study, ibrutinib treatment successfully reprogrammed macrophages for increasing CD8+ T cells to assist with tumour control in PC (125). Moreover, the synergistic activity of ibrutinib with ICIs has also been described in preclinical models, including regulating tumour-induced immune tolerance by enhancing the activity of tumour-infiltrating cells and reducing the secretion of immunosuppressive cytokines (126). A recent phase Ib/II study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed or refractory solid tumours (127). Although ibrutinib plus durvalumab had an acceptable safety profile, the combination showed limited activity with an overall RR of 2% and median OS of 4.2 months for 49 PC patients. Another randomized phase II study evaluated the effect of a second-generation BTK inhibitor in patients with advanced PC using acalabrutinib alone or in conjunction with pembrolizumab, an anti-PD-1 antibody (128). The monotherapy and combination treatments both showed minimal clinical benefit. Therefore, additional trials are needed to refine the dual inhibition of BTK and the PD-1/PD-L1 pathway in PC.

**Angiogenesis**

Various stromal components, such as collagen, fibronectin, HA, VEGF, TGF-β, and CTGF are closely associated with a fibrotic and hypoxic tumour condition, which forms a hard mass and releases several proangiogenic factors, including VEGF, MMP-9, interleukin-8, and fibroblast growth factor-2 (129). These stromal cells and ECM play a crucial role in stimulating or inhibiting angiogenesis via multiple pathways and numerous genetic alterations in PC (56). Several studies have already demonstrated that overexpression of VEGF is related with tumour progression and a poor prognosis, and antiangiogenic treatment reduces tumour cell growth (130). Consequently, anticipating that antiangiogenic therapy could be effective for PC, a single-arm phase II trial with a combination of bevacizumab and gemcitabine did show clinical benefits (131). However, in two large phase III studies, the addition of bevacizumab to chemotherapy failed to reach the primary endpoint of OS (70, 71). Despite several subsequent clinical trials using bevacizumab and other chemotherapy backbones, no treatment benefits were reported (130).

Moreover, subsequent phase III clinical trials of antiangiogenic agents targeting vascular endothelial growth factor receptor (VEGFR) or VEGF, including axitinib, sorafenib, and aflibercept, showed no significant prolongation of OS (56, 72–74). Such findings are also consistent with two meta-analyses, that indicated no increase in OS with any VEGF or VEGFR-targeting treatment (130, 132). There are various explanations for the limited clinical outcomes of antiangiogenic agents in PC (133). Antiangiogenic therapy may inhibit the blood supply to tumours and inevitably diminish the drug delivery, which would partially explain the combined need for inhibition of angiogenesis and alternative mechanisms in the treatment of PC (134). Antiangiogenic therapy per se may support a conversion to a more aggressive phenotype, promoting the induction of invasive and treatment-resistant tumours (129). In addition, the angiogenesis pathway comprises a complex network of crosstalk with many parallel
cascades, so its inhibition may induce compensatory upregulation of proangiogenic factors, thereby paradoxically increasing tumour growth (56). Moreover, an adaptive response to hypoxia primarily mediated by HIFs confers more aggressive phenotypes in PC cells (129). Finally, continuous hypoxic microenvironment remodelling can stimulate the regulation of autophagy and generation of reactive oxygen species and alternative pathways, including the metabolism of glucose or glutamine, while also contributing to therapeutically resistant behaviour of PC (135). Therefore, considering its complex and multifaceted functionality, further studies of antiangiogenic therapy in PC are needed to identify the best combination partners for synergistic effects, especially with stromal depletion strategies that target specific stromal features. Exploring potential biomarkers will also be important to select the appropriate PC patient populations.

**Immune Cells**

The ability to evade immune surveillance is a recognized hallmark in PC biology (136). Since PC is also well characterized by immune-quiescent desmoplastic stroma and the dominance of immunosuppressive cells, some recent research has been focusing on the development of immune-based therapies for PC (57). One promising immunotherapeutic strategy is to stimulate T-cell priming and dendritic cell activation, as the resulting activation of tumour-specific T cells and their migration into the TME may be the key to surmounting innate immune suppression and correcting the lack of effector T cells (17, 58). One of the most widely evaluated PC vaccines is GVAX, which is an irradiated allogeneic whole tumour cell vaccine engineered to express a granulocyte-macrophage colony-stimulating factor (137). In early phase studies, GVAX has been found to be tolerable and effective in promoting the development of antitumour immunity (138, 139). These results then prompted a randomized phase 2 trial evaluating GVAX pancreas in combination with cyclophosphamide followed by CRS-207, a live-attenuated listeria vaccine expressing a PC-associated antigen mesothelin in previously treated metastatic PC. This triple combination therapy demonstrated a longer OS with minimal toxicity and enhanced mesothelin-specific CD8 cytotoxic cells correlated with the improved OS (75). However, a subsequent phase IIb trial (ECLIPSE) failed to show any superiority of this combination over chemotherapy (140). This may have been due to the failure of sufficient T-cell induction or quick exhaustion of effective immune cells (58). Plus, major contributors, including CAFs, MDSCs, or TAMs may regulate multiple immunosuppressive mechanisms, indicating the dynamic nature and heterogeneity of the immune response in PC (18, 57). Thus, the addition of a new combination approach seems to be the ideal strategy to achieve a more impressive response in PC, and ICIs could be such a treatment.

ICIs can lead to T-cell activation, thereby generating an effective immune response. Nevertheless, a broad spectrum of clinical trials for each ICI monotherapy has shown limited clinical success. For example, a phase II study with ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), showed no significant improvement in survival (76). In early clinical trials, other single-agent anti-PD-1 agents, including pembrolizumab and nivolumab have also been ineffective in the treatment of PC (141, 142). Consequently, combination approaches have been explored to enhance the immune responses for better therapeutic effects when treating PC. For a dual inhibition setting, a recent randomized phase II study evaluated 65 previously treated metastatic PC patients for the efficacy of durvalumab alone or in combination with the anti-CTLA-4 antibody, tremelimumab (77). Although the combination therapy produced a modest improvement with a 3-month disease control rate (DCR) of 9.4%, as the desired threshold efficacy (10%) was not achieved, the study was closed. Another ongoing clinical study is evaluating ipilimumab in combination with nivolumab (NCT01928394) (137).

ICIs in combination with chemotherapeutic agents are an increasing focus as an alternative option for the treatment of PC. A recent phase Ib trial reported that an ipilimumab and gemcitabine combination was safe, including a delayed response in one patient (143). Tremelimumab plus gemcitabine has also demonstrated a tolerable toxicity with median survival of 7.4 months (144). Moreover, the preliminary results from a randomized phase 2 trial (CCTG PA.7) evaluating the efficacy of gemcitabine and nab-paclitaxel in combination with durvalumab and tremelimumab showed a median PFS of 2.5 months and median OS of 8.5 months (NCT02879318) (145). Plus, pembrolizumab was combined with gemcitabine and nab-paclitaxel in a phase Ib/II study including 17 patients with metastatic PC. Of the 11 evaluable chemotherapy naïve patients, this combination showed an interesting outcome with a DCR of 100% and median PFS of 9.1 months, which seems to be much better than typically reported for first-line chemotherapy (78).

Combining of ICIs with a vaccine or other immunomodulatory molecules is another potentially effective regimen, and is currently under clinical investigation to determine the efficacy in PC. Le et al. evaluated combining ipilimumab and the GVAX vaccine in a phase Ib trial, where 30 patients were randomly assigned to single-agent ipilimumab versus ipilimumab combined with GVAX. As a result, the combination patients showed a better 1-year OS benefit versus ipilimumab alone (27% versus 7%), prompting additional GAVX clinical trials with various modalities (146). Numerous similar clinical trials are also underway, including agonist CD40 antibodies, indoleamine 2,3-dioxygenase inhibitors, BTK inhibitors, anti-lymphocyte activating gene-3 monoclonal antibodies, CXCL/CXCR inhibitors, FAK inhibitors, T cell immunoglobulin-related agents, and adoptive cell transfer therapy (so-called ‘CAR T-cell therapy’). Although most of these trials are still ongoing, combined strategies using different therapeutic approaches with ICIs may provide supporting evidence to optimize PC treatment using ICIs (137, 147).

**DISCUSSION AND PERSPECTIVE**

Despite substantial advances in the development of new agents and an improved understanding of PC genetics, cytotoxic-backboned chemotherapy remains the key treatment with only a few novel agents being translated into clinical practice. Current research is focused on targeting the specific component of the PC tumour stroma, yet the results so far are disappointing, and there
have been few significant advanced in antiangiogenic therapy or immunotherapy. The PC microenvironment is characterized by increased desmoplasia and energy metabolic disorders (28). Plus, accumulating evidence has revealed that the PC stroma is enriched with CAFs or PSCs that produce excessive amounts stromal elements and a matrix, leading to a desmoplastic process (59). These components are also responsible for the generation of a rigid barrier that results in elevated tumour pressure, a hypovascular microenvironment, and attenuated drug delivery (17). A rich stroma and severe fibrotic reaction have also been shown to play a role in remodelling the TME (28). In addition to the mechanical factors, TME alterations in PC can also support the metabolism of cancer cells, even in a nutrient-depleted and hypoxic TME. In particular, an amplified desmoplastic reaction can significantly impair the immune response and augment the immune tolerance (8). Thus, recent data also emphasizes the importance of multiple targeted approaches, including stromal depletion and immune modulation. Therefore, proactively designed combination strategies are needed for more successful development of stroma-targeting agents. Plus, an improved understanding of the interaction complexity between tumour cells and the heterogeneous TME components will help to identify stromal-based biomarkers for categorizing patients who can receive clinical benefit in PC.

Molecular classification could also help to improve patient selection and enable better differentiation of responders and non-responders. For example, as an immunogenic subtype exhibits an upregulation of immune-related genes, this subtype could feasibly be treated with ICIs (148). Meanwhile, a basal-like subtype may benefit more from gemcitabine-based regimens than from FOLFIRINOX (149). Plus, the presence of pancreatic stellate cells in an ADEX subtype could also imply resistance to gemcitabine or radiotherapy (150). More recently, Tiriac et al. performed drug sensitivity profiling of PC organoid models and identified novel functional subtypes for defining gene expression signatures to predict chemotherapy sensitivity (151). Although further studies are required to validate these results in PC, designing and testing novel specific targeted therapies for each subtype may help to avoid unnecessary treatments and expedite the application of an effective drug combination.

**AUTHOR CONTRIBUTIONS**

PE and BK drafted the manuscript. IC managed and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

PE and IC would like to acknowledge National Health Service funding to the National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.

**REFERENCES**

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med (2014) 371:1039–49. doi: 10.1056/NEJMra1404198
2. Cid-Arregui A, Juarez V. Perspectives in the Treatment of Pancreatic Adenocarcinoma. World J Gastroenterol (2015) 21:9297–316. doi: 10.3748/wjg.v21.i31.9297
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med (2011) 364:1817–25. doi: 10.1056/NEJMoa1101192
4. Braith E, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative Effectiveness and Resource Utilization of Nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX or Gemcitabine for the First-Line Treatment of Metastatic Pancreatic Adenocarcinoma in a US Community Setting. Cancer Manag Res (2017) 9:141–8. doi: 10.2147/CMAR.S126073
5. Von Hoff DD, Ervin T, Arena FP, Chiofaro EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine. N Engl J Med (2013) 369:1691–703. doi: 10.1056/NEJMoa1304369
6. Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. Cancers (Basel) (2018) 10:34. doi: 10.3390/cancers10020034
7. Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the Tumor Microenvironment in Pancreatic Cancer. Ann Gastroenterol Surg (2019) 3:130–7. doi: 10.1002/ags3.12225
8. Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Tsimpson R. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Gastroenterology (2018) 154:820–38. doi: 10.1053/j.gastro.2017.11.280
9. Lafia KJ, Melder LG. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Am J Pathol (2019) 189:44–57. doi: 10.1016/j.ajpath.2018.09.009
10. Brunnner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci (2019) 20:4543. doi: 10.3390/ijms20184543
11. Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, et al. New Therapeutic Targets in Pancreatic Cancer. Cancer Treat Rev (2019) 81:101926. doi: 10.1016/j.ctrv.2019.101926
12. Hilgers W, Kern SE. Molecular Genetic Basis of Pancreatic Adenocarcinoma. Genes Chromosomes Cancer (1999) 26:1–12. doi: 10.1002/(SICI)1098-2264(199909)26:1<1::AID-GICC1>3.0.CO;2-X
13. Canto MI, Hurban RH, Fishman EK, Kamel IR, Schlick R, Zhang Z, et al. Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology (2012) 142:796–e15. doi: 10.1053/j.gastro.2012.01.005
14. Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer. Nature (2016) 531:47–52. doi: 10.1038/nature16965
15. Maurer V, Holmstrom SR, He J, Laise P, Su T, Ahmed A, et al. Experimental Microdissection Enables Functional Harmonisation of Pancreatic Cancer Subtypes. Gut (2019) 68:1034–43. doi: 10.1136/gutjnl-2018-317706
16. Abbassi R, Schmid RM. Evolving Treatment Paradigms for Pancreatic Cancer. Visc Med (2019) 35:362–72. doi: 10.1172/JCI30082
17. Sarantis P, Koustas E, Papadimitrioupolou A, Papavassiliou AG, Karamouzis MV. Pancreatic Ductal Adenocarcinoma: Treatment Hurdles, Tumor Microenvironment and Immunotherapy. World J Gastrointest Oncol (2020) 12:173–81. doi: 10.4251/wjg.v12.i2.173
18. Storz P, Crawford HC. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Gastroenterology (2020) 158:2072–81. doi: 10.1053/j.gastro.2020.02.059
19. von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The Role of Stromal Cancer-Associated Fibroblasts in Pancreatic Cancer. J Hematol Oncol (2017) 10:76. doi: 10.1186/s13045-017-0448-5
20. Omary MB, Lugea A, Lowe AW, Pandol SJ. The Pancreatic Stellate Cell: A Star on the Rise in Pancreatic Diseases. World J Gastrointest Oncol (2019) 11:47. doi: 10.4251/wjg.v11.i2.43
21. Chen X, Song E. Turning Foes to Friends: Targeting Cancer-Associated Fibroblasts. Nat Rev Drug Discov (2019) 18:99–115. doi: 10.1038/s41573-018-0004-1
Response to Immunotherapy. *Immunity* (2018) 49:178–93.e7. doi: 10.1016/j.immuni.2018.06.006

62. Pirozzi VJ, Pipas JM, Koong A, Giaccia A, Bahary N, Krishnamurthi SS, et al. Phase I/II Study of PEGylated Recombinant Human Hyaluronidase and Gemicatibine in Patients With Advanced Pancreatic Cancer. *Clin Cancer Res* (2016) 22:2484–54. doi: 10.1158/1078-0432.CCR-15-1020

63. Tempero MA, Cutsem EV, Sigal D, Oh D-Y, Fazio N, Macarulla T, et al. HALO

64. Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Grif

65. Pirozzi VJ, Pipas JM, Koong A, Giaccia A, Bahary N, Krishnamurthi SS, et al. Phase I/II Randomized Study of FOLFRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. *J Clin Oncol* (2019) 37:1062–9. doi: 10.1001/jco.2018.01295

66. Cook RW, Wheatley K, Allan DB, Rowland M, Lenehan M, Tattersall M, et al. A Randomized Trial of比方ether Hyaluronidase Inhibition by Pegylated Recombinant Hyaluronidase (PEGPH20) or Placebo in Patients With Pancreatic Cancer: A Randomised Phase 2 Study. *Ann Oncol* (2019) 30:iv126. doi: 10.1093/annonc/mdz154.001

67. Zhen DB, Grif
Edwards et al. Targeting Stroma in Pancreatic Cancer

Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 691185

Evidences and Future Directions. World J Gastroenterol (2017) 23:5875–86. doi: 10.3748/wjg.v23.i32.5875

113. Han W, Cao F, Chen M-b, Li Z, Wang H-b, Yu M, et al. Prognostic Value of SPARC in Patients With Pancreatic Cancer: A Systematic Review and Meta-Analysis. PloS One (2016) 11:e0145803–e. doi: 10.1371/journal.pone.0145803

114. Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, et al. Phase II Study of Albumin-Bound Nab-Paclitaxel Plus Gemcitabine Administered to Chinese Patients With Advanced Pancreatic Cancer. Cancer Chemother Pharmacol (2013) 71:1065–72. doi: 10.1007/s00280-013-2102-4

115. Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, et al. SPARC Expression Did Not Predict Efficacy of Nab-Paclitaxel Plus Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clin Cancer Res (2015) 21:4811–8. doi: 10.1158/1078-0432.CCR-14-3222

116. Tabernero J, Chioarean EG, Infantes JR, Hingorani SR, Gajate P, et al. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist (2015) 20:143–50. doi: 10.1634/theoncologist.2014-0394

117. Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Koval J, et al. SPARC-Independent Delivery of Nab-Paclitaxel Without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther (2016) 15:680–8. doi: 10.1158/1535-7163.MCT-15-0764

118. Cullis J, de Nola D, Avanzo A, Barui S, Maier AS, Bar-Sagi D. Macropinocytosis of Nab-Paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Res (2017) 75:182–90. doi: 10.1158/2326-6066.CIR-16-0125

119. Pal Singh S, Dammeyer F, Hendriks RW. Role of Bruton’s Tyrosine Kinase in B Cells and Malignancies. Mol Cancer (2018) 17:57. doi: 10.1186/s12943-018-0779-z

120. Good L, Benner B, Carson WE. Bruton’s Tyrosine Kinase: An Emerging Targeted Therapy in Myeloid Cells Within the Tumor Microenvironment. Cancer Immunol Immunother: CIIT (2021) 1–13. doi: 10.1007/s00262-021-02908-5

121. Mesess JK, Liou GY. Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option. Cancers (Basel) (2021) 13:2199. doi: 10.3390/cancers13092198

122. Masso-Valles D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, et al. Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma. Cancer Res (2015) 75:1675–81. doi: 10.1158/0008-5472.CAN-14-2852

123. Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-Talk Drives Antitumor Activity. Cancers (Basel) (2021) 13:2439. doi: 10.3390/cancers13092439

124. Gunderson AJ, Kanda ME, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-Talk Drives Pancreatic Cancer. Cancer Discov (2016) 6:270–85. doi: 10.1158/2159-2890.CD-15-0827

125. da Guinha-Bang C, Niemann CU. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. Drugs (2018) 78:1653–63. doi: 10.1007/s40265-018-01003-6

126. Horton D, Asco C, Veeser M, Luke JJ, Chandler J, Balmanoukian A, et al. Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients With Pretreated Solid Tumors. Oncology (2019) 97:102–11. doi: 10.1159/000505071

127. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, et al. Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer. J Immunother Cancer (2020) 8:000587. doi: 10.1159/jitc-2020-000587

128. Zhang ZJ, Jiang ZB, Liu JJ, Qin YX, Xu J, et al. Role of Angiogenesis in Pancreatic Cancer Biology and Therapy. BioMed Pharmacother (2018) 108:1135–40. doi: 10.1016/j.biopha.2018.09.017
130. van Mackelenbergh MG, Stroes CI, Spijkervt R, van Eijck CHJ, Wilming JW, Blijswijk MF, et al. Clinical Trials Targeting the Tumor Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Cancers* (2019) 11:588. doi: 10.3390/cancers11050588

131. Kindler KL, Friberg G, Singh DA, Locker G, Nattam S, Kozlof M, et al. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. *J Clin Oncol* (2005) 23:8033–40. doi: 10.1200/JCO.2005.10.9661

132. Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, et al. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. *Target Oncol* (2018) 13:447–59. doi: 10.1007/s11523-018-0578-x

133. Chandana S, Babiker HM, Mahadevan D. Therapeutic Trends in Pancreatic Ductal Adenocarcinoma (PDAC). Expert Opin Investig Drugs (2019) 28:161–77. doi: 10.1080/13543784.2019.1557145

134. Annese T, Tamma R, Ruggieri S, Ribatti D. Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. *Cancers* (2019) 11:381. doi: 10.3390/cancers11030381

135. Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting Hypoxic Ductal Adenocarcinoma (PDAC). *Expert Opin Investig Drugs* (2020) 28:102016. doi: 10.1016/j.ctrv.2020.102016

136. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. *Cell* (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

137. Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, et al. Immunotherapy for Pancreatic Cancer: A 2020 Update. *Cancer Treat Rev* (2020) 86:102016. doi: 10.1016/j.ctrv.2020.102016

138. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma. A Phase II Trial of Safety, Efficacy, and Immune Activation. *Clin Cancer Res* (2008) 14:1455–63. doi: 10.1158/1078-0432.CCR-07-0371

139. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence With Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. *Clin Cancer Res* (2008) 14:1455–63. doi: 10.1158/1078-0432.CCR-07-0371

140. O’Kane GM, Grünwald BT, Jang GH, Masoomian M, Picardo S, Grant RC, et al. GATA6 Expression Distinguishes Classical and Basal-Like Subtypes in Advanced Pancreatic Cancer. *Clin Cancer Res* (2020) 26:4901–10. doi: 10.1158/1078-0432.CCR-19-3724

141. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients With Advanced Solid Tumors. *Clin Cancer Res* (2011) 253:328–35. doi: 10.1097/SLA.0b013e3181fd271c

142. Le DT, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Immunotherapy Alone or in Sequence With Cyclophosphamide for Metastatic Pancreatic Cancer: Pre-Clinical and Clinical Studies. *Cancers* (Basel) (2019) 11:381. doi: 10.3390/cancers11030381

143. Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson IIIA, et al. Phase Ib Study. *oncologist n/a* (2020) 25(3):e808–15. doi: 10.1634/oncologist.2019-0473

144. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr., Bagalà C, et al. A Phase I Dose Escalation Trial of Tremelimumab (CP-675,206) in Combination With Gemcitabine in Chemotherapy-Naive Patients With Metastatic Pancreatic Cancer. *Ann Oncol* (2014) 25:1750–5. doi: 10.1093/annonc/mdu205

145. Renouf DJ, Dhani NC, Kavan P, Jonker DJ, Wei A-C, Hsu T, et al. The Canadian Cancer Trials Group PA.7 Trial: Results From The Safety Run in of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) Versus GEM, Nab-P, Durvalumab (D), and Tremelimumab (T) as First-Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). *J Clin Oncol* (2018) 36:349–41. doi: 10.1200/JCO.2018.36.4_suppl.349

146. Le DT, Lutz E, Uram JN, Sugar EA, Onners R, Solt S, et al. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. *J Immunother* (2013) 36:382–9. doi: 10.1097/CJI.0b013e31829bf7a2

147. O’Kane GM, Grünwald BT, Jang GH, Masoomian M, Picardo S, Grant RC, et al. アイピルリムアバ Expression Distinguishes Classical and Basal-Like Subtypes in Advanced Pancreatic Cancer. *Clin Cancer Res* (2020) 26:4901–10. doi: 10.1158/1078-0432.CCR-19-3724

148. Martinez-Userso J, Martin-Galan M, Garcia-Foncillas J. The Match Between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. *Cancers* (2021) 13:322. doi: 10.3390/cancers13020322

149. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Contextual Regulation of Pancreatic Cancer Stem Cell Phenotype and Radioresistance by Pancreatic Stellate Cells. *Radiother Oncol* (2014) 111:243–51. doi: 10.1016/j.radonc.2014.03.014

150. Al-Assar O, Demicioglu F, Lunardi S, Gaspar-Carvalho MM, McKenna WG, Muschel RM, et al. Contextual Regulation of Pancreatic Cancer Stem Cell Phenotype and Radioresistance by Pancreatic Stellate Cells. *Radiother Oncol* (2014) 111:243–51. doi: 10.1016/j.radonc.2014.03.014

Conflict of Interest: IC: Advisory Board: Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, Oncology International, Pierre Fabre, Boehringer Ingelheim. Research funding: Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono. Honorarium: Eli-Lilly.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Edwards, Kang and Chau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.